Marshall Wace, LLP Candel Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $74.4 Billion
- Q1 2025
A detailed history of Marshall Wace, LLP transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 234,597 shares of CADL stock, worth $1.61 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
234,597Holding current value
$1.61 Million% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CADL
# of Institutions
86Shares Held
15.4MCall Options Held
536KPut Options Held
335K-
Baker Bros. Advisors LP New York, NY2.44MShares$16.7 Million0.16% of portfolio
-
Acorn Capital Advisors, LLC New York, NY2.15MShares$14.7 Million8.46% of portfolio
-
Northpond Ventures, LLC1.94MShares$13.3 Million48.35% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.74MShares$11.9 Million0.0% of portfolio
-
Portolan Capital Management, LLC Boston, MA881KShares$6.04 Million0.41% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $198M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...